ArticleMolecules (Basel, Switzerland)2026
Systematic Evaluation of Structure-Property-Biocompatibility Relationships of Polyhydroxyalkanoate Copolymers for Advanced Veterinary Applications.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Polyhydroxyalkanoates in Veterinary Medicine: Biosynthesis, Material Modifications and Clinical Applications.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Polyhydroxyalkanoates (PHAs) are a family of microbial polyesters distinguished by their excellent biocompatibility and tunable degradation profiles. However, systematic evaluation of the interaction effect between their chemical structure, material properties, and biological performance remains limited, particularly in veterinary medicine applications. In this study, we conducted comprehensive in vitro and in vivo evaluations of five commercially available PHA (co)polymers: poly(3-hydroxybutyrate) (PHB); poly(3-hydroxybutyrate-co-4-hydroxybutyrate) containing 5 mol% or 15 mol% 4-hydroxybutyrate monomer (P34HB 5%, P34HB 15%); and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) containing 5 mol% or 15 mol% 3-hydroxyvalerate monomer (PHBV 5%, PHBV 15%). Material characterization confirmed that the introduction of proper comonomers effectively reduced crystallinity and accelerated the degradation process. Biological assays demonstrated quite excellent cytocompatibility and hemocompatibility among all tested PHA materials. Notably, P34HB 5% nanoparticles promoted human umbilical vein endothelial cell (HUVEC) migration. In a 12-week murine subcutaneous implantation model, the PHBV 15% group exhibited the thinnest fibrous capsule formation and the mildest inflammatory response. Furthermore, intramuscular injection of nanoparticles revealed favorable muscle tissue compatibility in all groups. These results provided a co-polymer ratio-based justification for PHA selection, thus providing support for the application of these biomaterials in veterinary drug delivery platforms, wound dressings, and biodegradable implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.